RNA Outsourcing Resources

31. Dispelling Common Clinical Trial Oversight Myths 6/17/2025

    Many clinical trial oversight problems can be avoided or mitigated by sponsor understanding root causes and being a proactive collaborator with its partners.

32. Built Like A Tech Company: Why CROs Need A New Operating System 10/20/2025

    See why building digital, automated infrastructure is essential, and better aligns CROs with today's speed, compliance, and innovation needs.

33. How A Strategic Bioanalysis CRO Partnership Empowers Sponsors 1/8/2026

    Choosing the right bioanalysis CRO is vital to avoid costly delays. Sponsors need evaluation strategies that prioritize proven quality, predictable timelines, and submission-ready data.

34. Consolidating The Supply Chain For mRNA 2/12/2024

    Learn about the first end-to-end cGMP facility that was developed for mRNA manufacturing to address the shortage of CDMOs and the inadequate and inefficient supply chain options for sourcing GMP mRNA.

35. Lipids CDMO Services: Custom Excipients Tailored To Your Needs 4/27/2026

    Advance your lipid‑based programs with a CDMO partner equipped to deliver customized excipients, proven scale‑up expertise, and reliable support from early development through commercialization.

36. Bio/Pharmaceutical Facility Validation And Environmental Monitoring 6/11/2026

    Gain insight into how experienced validation and monitoring partners help organizations establish compliant operations, maintain facility performance, manage risk, and support long-term operational excellence.

37. Going Global: How Working With A CRO Can Benefit Clinical Trials 9/12/2023

    Contract research organizations can be invaluable partners in clinical trials. Dive into the full spectrum of benefits you'll experience by partnering with a globally established and well-resourced CRO.

38. The M.O. Behind Choosing A CDMO: Three Considerations For New Drug Developers 11/29/2021

    The greatest challenge in drug development can be finding a team capable of carrying a molecule through the complexities that lie between the research lab and the patient’s bedside. Discover three considerations that build a foundation for partnership.

39. New Perspectives On Accelerating Genetic Nanomedicines Through The Regulatory Pathway 3/1/2024

    Discover how regulatory bodies are adopting a risk-based approach to address the unique challenges of genetic nanomedicines, and stakeholder engagement is essential.

40. Cell And Virus Banking In OV Development And Manufacturing 5/14/2024

    Delve into the exciting potential of OVs, including the critical role of cell and virus seed banks, and discover key considerations for establishing cell and virus banks for OV production.